Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD3 | P35462 | 12/20 | 1.00 |
| ▸ | DRD2 | P14416 | 12/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.72 |
| ▸ | TSHR | P16473 | 1/20 | 0.72 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.72 |
| ▸ | CASP1 | P29466 | 1/20 | 0.72 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.71 |
| ▸ | DRD1 | P21728 | 2/20 | 0.58 |
| ▸ | DRD4 | P21917 | 2/20 | 0.58 |
| ▸ | DRD5 | P21918 | 2/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7383021 | 0.93 | DRD3 (1.00) | DRD3DRD2CYP2D6TSHRNFKB1 | |
| SCHEMBL7355118 | 0.84 | DRD3 (1.00) | DRD3DRD2CYP2D6TSHRNFKB1 | |
| SCHEMBL7346180 | 0.84 | DRD3 (1.00) | DRD3DRD2CYP2D6TSHRNFKB1 | |
| SCHEMBL872942 | 0.84 | DRD3 (1.00) | DRD3DRD2CYP2D6TSHRNFKB1 | |
| SCHEMBL7351587 | 0.82 | DRD3 (0.86) | DRD3DRD2CYP2D6TSHRNFKB1 | |
| SCHEMBL7380006 | 0.81 | DRD3 (0.70) | DRD3DRD2NFKB1DRD1DRD4 | |
| SCHEMBL10657469 | 0.81 | DRD3 (0.70) | DRD3DRD2NFKB1DRD1DRD4 | |
| SCHEMBL7349038 | 0.81 | DRD3 (1.00) | DRD3DRD2CYP2D6TSHRNFKB1 | |
| SCHEMBL8844122 | 0.80 | DRD2 (0.67) | DRD3DRD2CYP2D6TSHRNFKB1 | |
| SCHEMBL7351584 | 0.79 | DRD2 (1.00) | DRD3DRD2CYP2D6TSHRNFKB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5594024-A | ANTIDEPRESSANTS; TREATMENT OF NARCOLEPSY, SCHIZOPHRENIA, DRUG ABUSE | THE UPJOHN COMPANY (US) | 1997-01-14 | — | — | US | disclosed |
| US-5462947-A | Nervous system disorders | THE UPJOHN COMPANY (US) | 1995-10-31 | — | — | US | disclosed |
| EP-0641320-A1 | NEW CENTRALLY ACTING SUBSTITUTED PHENYLAZACYCLOALKANES | PHARMACIA & UPJOHN COMPANY (US) | 1995-03-08 | — | — | EP | disclosed |
| WO-1992018475-A2 | SUBSTITUTED PHENYLAZACYCLOALKANES AS CNS AGENTS | THE UPJOHN COMPANY (US) | 1992-10-29 | — | — | WO | disclosed |